Tyvyt (sintilimab)

P2, N=47, Not yet recruiting, Sun Yat-sen University

Postoperative pathology combined with fluorescence in situ hybridization (FISH) testing demonstrated MDM2/CDK4 amplification, confirming dedifferentiated liposarcoma (DDLPS). The patient recovered well postoperatively and was discharged following adjuvant radiotherapy (IMRT; 50 Gy in 25 fractions), chemotherapy (AD regimen), and immunotherapy (sintilimab).Through this case, we mainly understand the characteristics of the disease onset, special diagnosis, and main treatment methods.

We report a case of a patient with gastric carcinoma who developed delayed-onset TEN after receiving four cycles of neoadjuvant sintilimab combined with the SOX regimen (S-1 and oxaliplatin)...Early recognition and timely immunosuppressive treatment are essential for favorable outcomes. Further investigation into the mechanisms and predictive factors of PD-1 inhibitor-induced TEN is warranted.

P2, N=150, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> Mar 2029 | Trial primary completion date: Feb 2025 --> Mar 2026

P3, N=590, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Trial primary completion date: Mar 2026 --> Sep 2026

Patients received a regimen consisting of oxaliplatin, sintilimab, capecitabine, and IL‑2 administered in a three‑week cycle, with response evaluations performed after every two cycles. These findings warrant studies to validate this regimen as a novel treatment paradigm for rectal cancer. ClinicalTrials.gov registration: NCT06108596.

PA-MSHA improved immune cells function and enhanced their antitumor effects against STK11 mutant NSCLC, which was associated with the activation of the STING pathway.

P2, N=43, Recruiting, Tianjin Medical University Cancer Institute and Hospital

Following neoadjuvant chemoimmunotherapy comprising XELOX and sintilimab, diagnostic laparoscopy identified a concurrent AMA accompanied by pseudomyxoma peritonei (PMP). This rare case highlights the critical importance of comprehensive preoperative imaging and meticulous surgical evaluation in the diagnosis of uncommon synchronous malignancies. Furthermore, the observed alteration in molecular phenotype following chemoimmunotherapy suggests that such treatment modalities may influence tumor biology.

P1, N=21, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

P2, N=241, Recruiting, Fudan University

P2/3, N=33, Completed, Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting --> Completed | N=80 --> 33 | Trial primary completion date: Mar 2022 --> Oct 2025